Eterna Therapeutics Investigates ERNA-101 in Cancer Models
Eterna Therapeutics, a preclinical-stage company, announced a research collaboration with MD Anderson Cancer Center to evaluate its lead induced mesenchymal stem cell therapy, ERNA-101, for treating ovarian and breast cancers. ERNA-101, a proprietary allogenic cell therapy, aims to stimulate antitumor immunity. The research will assess ERNA-101’s effects both in vitro and in vivo, with potential future studies exploring […]
FDA Approves StemCyte’s REGENECYTE™ Cord Blood Therapy
StemCyte Inc. announced FDA approval of its REGENECYTE™ cord blood stem cell therapy for treating blood and immune system disorders, making them the first U.S.-based biotech company to receive such a biologics license for this therapy in 2024. REGENECYTE™ is an allogeneic therapy derived from umbilical cord blood. The company is also exploring other applications […]
BioRestorative Therapies Expands Stem Cell Research with New York State License
In a significant advancement for regenerative medicine, BioRestorative Therapies, Inc. has secured a provisional license from the New York State Department of Health (NYSDOH) to process allogeneic (non-autologous) donor tissue material, including stem cells, for medical research. This expansion builds upon their previous authorization, which was limited to autologous (self-donated) mesenchymal stem cells. This new […]
Pioneering Stem Cell Therapy Shows Promise in Alzheimer’s Treatment: Regeneration Biomedical Releases First Cohort Results
In a breakthrough for Alzheimer’s disease research, Regeneration Biomedical, Inc. recently presented promising findings from a Phase I clinical trial that delivers stem cell therapy directly into the brains of patients. Utilizing Wnt-activated, autologous, expanded, adipose-derived stem cells (RB-ADSCs), the therapy is designed to potentially slow or reverse the progression of Alzheimer’s. These specialized stem […]
Revolutionary Stem Cell Therapy: New Partnership Aims to Transform Orthopedic Treatments for Rotator Cuff Injuries
In an exciting leap for stem cell research and regenerative medicine, Regenerative Orthopedics & Sports Medicine (ROSM) has joined forces with Orthobiologics Research Initiative Inc. (ORI) in a groundbreaking study funded by the Maryland Stem Cell Research Fund. This innovative research, set for completion by December 2026, focuses on harnessing the healing potential of microfat […]
Factor Bioscience and Eterna Therapeutics Partner to Accelerate Advanced Cell Therapies for Cancer, Rare Diseases, and Autoimmune Disorders
In a groundbreaking collaboration that promises to reshape the future of medicine, Factor Bioscience and Eterna Therapeutics have announced an exclusive license agreement to accelerate the development of stem cell-based therapies for oncology, autoimmune disorders, and rare diseases. The agreement is centered around the utilization of Factor’s proprietary induced pluripotent stem cell (iPSC) technologies, which […]
MaxCyte and Kamau Therapeutics Partner to Accelerate Gene Correction with Groundbreaking Stem Cell Therapies for Genetic Diseases
In a groundbreaking move for stem cell therapies, MaxCyte, Inc. has entered into a strategic platform license agreement with Kamau Therapeutics, a clinical-stage company focused on gene correction. The collaboration will leverage MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to expedite the development of innovative therapies targeting genetic diseases. Kamau’s platform, built on homology-directed repair […]
Somite Therapeutics Achieves Key Milestone with FDA Orphan Drug and Rare Pediatric Disease Designations for SMT-M01 in Duchenne Muscular Dystrophy
Somite Therapeutics has announced a major breakthrough in the fight against Duchenne Muscular Dystrophy (DMD), securing both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the FDA for their lead therapeutic candidate, SMT-M01. These designations are critical in the development of therapies targeting rare diseases, offering benefits such as tax credits for […]
How Somite Therapeutics and OmniaBio Are Revolutionizing Cell Therapy for Duchenne Muscular Dystrophy
In an exciting new collaboration, Somite Therapeutics and OmniaBio Inc. have joined forces to advance Somite’s flagship cell therapy program, targeting the devastating genetic disorder Duchenne Muscular Dystrophy (DMD). This strategic partnership leverages Somite’s cutting-edge use of AI-driven cell replacement therapies and OmniaBio’s expertise in induced pluripotent stem cells (iPSCs) to bring hope to individuals […]
Justin Baldoni’s Chronic Pain Relief: How Stem Cell and Regenerative Therapy Transformed the Actor’s Health
Justin Baldoni, the talented actor and director known for his role in the recent box-office hit “It Ends With Us,” has revealed his journey through chronic pain and the revolutionary regenerative therapy that has given him a new lease on life. Baldoni, who suffered from various injuries including a herniated disk, damaged meniscus, and arthritis […]